Home » Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Httpsd1e00ek4ebabms cloudfront netproductioneea97105 5969 4dc5 b6a4 0dc67d5229f0

This post was originally published on this site.

Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector